DexCom (NASDAQ:DXCM) Stock Rating Lowered by BidaskClub

Share on StockTwits

BidaskClub cut shares of DexCom (NASDAQ:DXCM) from a strong-buy rating to a buy rating in a research report report published on Thursday, BidAskClub reports.

DXCM has been the topic of a number of other reports. UBS Group increased their price target on DexCom from $335.00 to $400.00 and gave the stock a neutral rating in a research report on Wednesday. Morgan Stanley increased their price target on DexCom from $377.00 to $428.00 and gave the stock an equal weight rating in a research report on Wednesday. Wells Fargo & Co began coverage on DexCom in a research report on Thursday, May 14th. They set an equal weight rating and a $420.00 price target on the stock. Bank of America reiterated a buy rating and issued a $500.00 price objective on shares of DexCom in a research report on Tuesday, July 28th. Finally, Cowen increased their price objective on DexCom from $430.00 to $450.00 and gave the company an outperform rating in a research report on Tuesday, July 7th. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. DexCom presently has an average rating of Buy and an average price target of $394.95.

Shares of DXCM opened at $435.54 on Thursday. DexCom has a 1 year low of $138.28 and a 1 year high of $446.50. The company has a current ratio of 7.58, a quick ratio of 5.41 and a debt-to-equity ratio of 1.28. The stock has a 50 day simple moving average of $410.52 and a 200-day simple moving average of $325.07. The stock has a market cap of $41.70 billion, a PE ratio of 198.88, a PEG ratio of 4.74 and a beta of 0.79.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, July 28th. The medical device company reported $0.79 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.48. The business had revenue of $451.80 million for the quarter, compared to analyst estimates of $415.21 million. DexCom had a return on equity of 29.01% and a net margin of 11.93%. DexCom’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.08 EPS. On average, sell-side analysts forecast that DexCom will post 2.45 EPS for the current fiscal year.

In related news, insider Andrew K. Balo sold 6,522 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $366.47, for a total transaction of $2,390,117.34. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Steven Robert Pacelli sold 1,531 shares of the firm’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $427.31, for a total value of $654,211.61. Following the sale, the executive vice president now directly owns 51,482 shares in the company, valued at approximately $21,998,773.42. The disclosure for this sale can be found here. Insiders sold a total of 63,293 shares of company stock worth $24,266,963 over the last 90 days. 0.69% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of DXCM. Norges Bank acquired a new stake in DexCom during the 4th quarter worth $200,017,000. Sands Capital Management LLC acquired a new stake in shares of DexCom in the 1st quarter valued at about $134,008,000. Janus Henderson Group PLC raised its stake in shares of DexCom by 34.0% in the 1st quarter. Janus Henderson Group PLC now owns 784,992 shares of the medical device company’s stock valued at $211,379,000 after purchasing an additional 199,106 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of DexCom by 45.3% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 557,647 shares of the medical device company’s stock valued at $150,158,000 after purchasing an additional 173,794 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of DexCom by 600.1% in the 1st quarter. Russell Investments Group Ltd. now owns 176,047 shares of the medical device company’s stock valued at $47,611,000 after purchasing an additional 150,902 shares during the period. 97.08% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Do stock splits help investors?

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

 

Latest News

Different Types of Research Papers
Different Types of Research Papers
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing


 
© 2006-2020 BBNS.